Antares Pharma, Inc., a longtime partner of Teva for several commercialized and in-development generic injectables, including the only AB-rated generic versions of Viatris’ EpiPen (epinephrine) family, is set to be acquired by California-based Halozyme Therapeutics for $5.60 a share, in a deal valuing Antares at roughly $960m.
Unanimously approved by both firms’ boards of directors, the transaction is expected to close in the first half of 2022, subject to customary closing conditions